JP2019524728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524728A5 JP2019524728A5 JP2019501578A JP2019501578A JP2019524728A5 JP 2019524728 A5 JP2019524728 A5 JP 2019524728A5 JP 2019501578 A JP2019501578 A JP 2019501578A JP 2019501578 A JP2019501578 A JP 2019501578A JP 2019524728 A5 JP2019524728 A5 JP 2019524728A5
- Authority
- JP
- Japan
- Prior art keywords
- platform
- antigen
- apc
- loaded
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 11
- 102000038129 antigens Human genes 0.000 claims 11
- 108091007172 antigens Proteins 0.000 claims 11
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 230000000240 adjuvant Effects 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 3
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(α-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 claims 2
- 210000003719 B-Lymphocytes Anatomy 0.000 claims 2
- YPHMISFOHDHNIV-FSZOTQKASA-N Cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 claims 2
- KKGQTZUTZRNORY-UHFFFAOYSA-N Fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229960000556 fingolimod Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960005486 vaccines Drugs 0.000 claims 2
- PITMOJXAHYPVLG-UHFFFAOYSA-N 2-acetyloxybenzoic acid;N-(4-ethoxyphenyl)acetamide;1,3,7-trimethylpurine-2,6-dione Chemical compound CCOC1=CC=C(NC(C)=O)C=C1.CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C PITMOJXAHYPVLG-UHFFFAOYSA-N 0.000 claims 1
- 102100013137 CD40 Human genes 0.000 claims 1
- 101710040446 CD40 Proteins 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 210000004443 Dendritic Cells Anatomy 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000030741 antigen processing and presentation Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000002458 infectious Effects 0.000 claims 1
Claims (17)
- 抗原提示の有効性及び抗原特異的免疫応答を増強するためのプラットフォームであって、
前記プラットフォームが、
a.少なくとも2種のサイトカインを含む組成物であって、前記2種のサイトカインがFlt−3L及びGM−CSFであり、Flt−3Lが8μg/kg以下で投与される量で存在する、組成物と、
b.抗原が負荷された抗原提示細胞(APC)の集団と、
を含む、プラットフォーム。 - 工程bにおいて、前記APCも、アジュバントと架橋されているか又はアジュバントが負荷されている、請求項1に記載のプラットフォーム。
- 前記抗原が負荷されたAPCの前記集団が、内因性免疫細胞に前記負荷された抗原を提示する、請求項1に記載のプラットフォーム。
- 前記APCがクラミジア活性化B細胞(CAB)である、請求項1に記載のプラットフォーム。
- 前記APCがCD40活性化B細胞である、請求項1に記載のプラットフォーム。
- 前記APCが樹状細胞である、請求項1に記載のプラットフォーム。
- 前記APCが人工APCである、請求項1に記載のプラットフォーム。
- 請求項1に記載のプラットフォームを製造する方法であって、
少なくとも2種のサイトカインを含む組成物であって、前記2種のサイトカインがFlt−3L及びGM−CSFであり、Flt−3Lが8μg/kg以下で投与される量で存在する、組成物と、
抗原提示細胞(APC)をシクロヘキシミド(CHX)又は同等なアジュバントにより処理した後に抗原と架橋して得た、前記抗原が負荷された抗原提示細胞(APC)の集団と、
を含む、プラットフォームを製造する工程を有する、
方法。 - 前記APCが、α−ガラクトシルセラミド(α-GalCer)又は同等なアジュバントに曝露されている、請求項1に記載のプラットフォーム。
- 前記APCが、FTY720又は同等なアジュバントに曝露されている、請求項1に記載のプラットフォーム。
- 前記プラットフォームが、1種超の抗原を含む、請求項1に記載のプラットフォーム。
- 前記抗原が、腫瘍関連抗原又はウイルス関連腫瘍抗原を含む、請求項1に記載のプラットフォーム。
- 前記抗原が、感染性因子の1つ以上の構成成分を含む、請求項1に記載のプラットフォーム。
- GM−CSFが、2μg/kg以下の投与される量で存在する、請求項1に記載のプラットフォーム。
- FTY720が、50μg/kg以下の範囲で投与される量で存在する、請求項10に記載のプラットフォーム。
- ワクチンを作製するための、請求項1に記載のプラットフォーム。
- ワクチンを作製するための、請求項10に記載のプラットフォーム。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662361591P | 2016-07-13 | 2016-07-13 | |
US62/361,591 | 2016-07-13 | ||
US201762444460P | 2017-01-10 | 2017-01-10 | |
US62/444,460 | 2017-01-10 | ||
PCT/US2017/041948 WO2018013820A1 (en) | 2016-07-13 | 2017-07-13 | Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019524728A JP2019524728A (ja) | 2019-09-05 |
JP2019524728A5 true JP2019524728A5 (ja) | 2020-08-13 |
JP7146732B2 JP7146732B2 (ja) | 2022-10-04 |
Family
ID=60951914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019501578A Active JP7146732B2 (ja) | 2016-07-13 | 2017-07-13 | 宿主抗原提示並びに宿主抗腫瘍及び抗病原体免疫を最適化するためのプラットフォーム及び方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11850279B2 (ja) |
EP (1) | EP3485002A4 (ja) |
JP (1) | JP7146732B2 (ja) |
CN (1) | CN109563481B (ja) |
AU (1) | AU2017294751B2 (ja) |
CA (1) | CA3030779A1 (ja) |
WO (1) | WO2018013820A1 (ja) |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4579945A (en) | 1982-04-29 | 1986-04-01 | Ribi Immunochem Research, Inc. | Purification of trehalose dimycolates |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4435386A (en) | 1982-05-26 | 1984-03-06 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4505900A (en) | 1982-05-26 | 1985-03-19 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4436728A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4505899A (en) | 1982-05-26 | 1985-03-19 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
US5108910A (en) | 1989-08-22 | 1992-04-28 | Immunex Corporation | DNA sequences encoding fusion proteins comprising GM-CSF and IL-3 |
US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
NZ314644A (en) | 1993-05-24 | 2000-11-24 | Immunex Corp | Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue |
US20020034517A1 (en) | 1995-10-04 | 2002-03-21 | Kenneth Brasel | Dendritic cell stimulatory factor |
US7150992B1 (en) | 1995-10-04 | 2006-12-19 | Innunex Corporation | Methods of preparing dendritic cells with flt3-ligand and antigen |
ATE432085T1 (de) | 1995-10-04 | 2009-06-15 | Immunex Corp | Stimulationsfaktor für dendriten |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
CA2216559A1 (en) | 1997-09-25 | 1999-03-25 | Michel Roberge | G2 checkpoint inhibitors and assay |
EP1144642B1 (en) | 1998-12-08 | 2010-05-26 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
AU8026800A (en) | 1999-10-15 | 2001-04-30 | Baylor Research Institute | Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses |
AU3069302A (en) | 2000-12-13 | 2002-06-24 | Immunex Corp | Method for generating immortal dendritic cell lines |
CA2453880A1 (en) | 2001-07-25 | 2003-02-06 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
EP1465657A4 (en) | 2001-12-18 | 2006-02-01 | Health Research Inc | METHOD FOR INCREASING IMMUNOGENICITY BY COVALENT COMPOUNDS OF ANTIGENS WITH PROTEINS ON THE SURFACE OF DENDRITIC CELLS |
KR100555211B1 (ko) | 2002-07-16 | 2006-03-03 | 주식회사 팬제노믹스 | 항암효과를 갖는 Her-2/neu DNA 백신 |
DE10326187A1 (de) * | 2003-06-06 | 2005-01-05 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Zellen als Träger für Bakterien |
GB0314682D0 (en) * | 2003-06-24 | 2003-07-30 | Isis Innovation | Materials and methods relating to the modulation of T cell response to soluble antigen |
US20070048254A1 (en) | 2005-08-24 | 2007-03-01 | Mirus Bio Corporation | Generation of dendritic cells |
BRPI0621599B1 (pt) | 2006-04-27 | 2021-07-27 | Cellid Co., Ltd | Vacina baseada em células b carregadas com o ligante da célula t exterminadora natural e antígeno |
US8003093B2 (en) | 2006-04-27 | 2011-08-23 | Seoul National University Industry Foundation | B cell-based vaccine loaded with the ligand of natural killer T cell and antigen |
GB0911042D0 (en) | 2009-06-25 | 2009-08-12 | Istituto Superiore Di Sanito | Treatment of tumorigenic cells in solid tumours |
AU2012321022B2 (en) | 2011-10-06 | 2017-03-23 | Immunovaccine Technologies Inc. | Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof |
KR101680164B1 (ko) * | 2012-02-10 | 2016-11-28 | 하쿠신코우세이카이재단 | 단구 증식제, 단구 증식용 배지, 단구의 제조방법, 수지상 세포의 제조방법, 및 수지상 세포 백신의 제조방법 |
ITRM20120083A1 (it) | 2012-03-07 | 2013-09-08 | Ist Superiore Sanita | Uso di modulatori dei recettori della sfingosina 1 fosfato per migliorare le immunizzazioni vaccinali. |
US20150087065A1 (en) | 2012-04-20 | 2015-03-26 | St. Jude Children's Research Hospital | Method for generation of conditionally immortalized hematopoietic progenitor cell lines with multiple lineage potential |
AU2014296887A1 (en) | 2013-08-02 | 2016-01-28 | Aduro Biotech Holdings, Europe B.V. | Combining CD27 agonists and immune checkpoint inhibition for immune stimulation |
WO2016130667A1 (en) * | 2015-02-10 | 2016-08-18 | Ohio State Innovation Foundation | Chlamydia-activated b cell platforms and methods thereof |
US10835601B2 (en) * | 2015-11-10 | 2020-11-17 | Ohio State Innovation Foundation | Methods and compositions related to accelerated humoral affinity |
-
2017
- 2017-07-13 US US16/317,247 patent/US11850279B2/en active Active
- 2017-07-13 JP JP2019501578A patent/JP7146732B2/ja active Active
- 2017-07-13 EP EP17828469.1A patent/EP3485002A4/en active Pending
- 2017-07-13 CN CN201780049510.XA patent/CN109563481B/zh active Active
- 2017-07-13 WO PCT/US2017/041948 patent/WO2018013820A1/en unknown
- 2017-07-13 CA CA3030779A patent/CA3030779A1/en active Pending
- 2017-07-13 AU AU2017294751A patent/AU2017294751B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Peng et al. | Particulate alum via pickering emulsion for an enhanced COVID‐19 vaccine adjuvant | |
WO2008005859A3 (en) | Dendritic cells generated using gm-csf and interferon alpha and loaded with heat-treated and killed cancer cells | |
CY1121211T1 (el) | Εμβολιο ιου ερπητα ζωστηρα | |
JP2011525191A5 (ja) | ||
JP2018076331A5 (ja) | ||
WO2013006842A3 (en) | Self-replicating rna prime - protein boost vaccines | |
WO2006120439A3 (en) | Cellular vaccine and use thereof | |
WO2017015463A3 (en) | Infectious disease vaccines | |
JP2017048187A5 (ja) | ||
WO2006095330A3 (en) | Methods and immunogenic cell preparations for treating antigen-associated diseases | |
WO2003009812A3 (en) | Use of glycosylceramides as adjuvants for vaccines against infections and cancer | |
BR112013021486A2 (pt) | lentes de contato de hidrogel contendo fosfina | |
JP2017534453A5 (ja) | ||
WO2005013891A3 (en) | Vaccines using pattern recognition receptor-ligand:lipid complexes | |
MX2019008303A (es) | Ácido ribonucleico modificado con nucleósidos para inducir una respuesta inmune contra el virus zika. | |
JP2015523307A5 (ja) | ||
CA2616344A1 (en) | A method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response | |
EP4043031A3 (en) | Zika viral antigen constructs | |
WO2008056174A3 (en) | Novel compositions and uses thereof | |
WO2013188627A3 (en) | Cationic lipid vaccine compositions and methods of use | |
BR112014004366A2 (pt) | dispositivo de curativo protetor para ferimento para o espaço oral e faríngeo | |
JP2015131825A5 (ja) | ||
MX2015014900A (es) | Formulaciones de gel para liberacion prolongada de compuestos volatiles. | |
EP4248992A3 (en) | Foot-and-mouth disease vaccine | |
JP2019524728A5 (ja) |